Live Breaking News & Updates on Planned Interim Analysis

Stay updated with breaking news from Planned interim analysis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Intercept Pharma (ICPT) Announces New Data Showing Potential of Fixed-Dose Combination of OCA and Bezafibrate to Normalize Multiple Biomarkers in PBC

Intercept Pharma (ICPT) Announces New Data Showing Potential of Fixed-Dose Combination of OCA and Bezafibrate to Normalize Multiple Biomarkers in PBC
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United States , Vaclav Hejda , M Michelle Berrey , Frederik Nevens , Nareg Sagherian , Antonio Civitarese , Cheng Zou , Lynda Szczech , Alexandre Louvet , Karen Preble , Intercept Pharmaceuticals Inc , Research Development , Company On Twitter , Warfarinthe International Normalized Ratio , Global Corporate Communications , Wall Street , European Association , Chief Medical Officer , Planned Interim Analysis , Active Controlled Trial Evaluating , Obeticholic Acid , Serum Biomarkers , Primary Biliary , Bezafibrate Fixed Dose Combinationintercept , Important Safety Information , Primary Biliary Cholangitisprimary ,

Intercept Announces New Data Showing Potential of Fixed-Dose Combination of OCA and Bezafibrate to Normalize Multiple Biomarkers in PBC to be Featured in Podium Presentation at EASL Congress 2023

Interim analysis of ongoing Phase 2 study shows combination of OCA 5-10 mg + bezafibrate 400 mg improved levels of multiple biochemical markers associated with clinical outcomes in PBC including ALP,. | June 7, 2023 ....

United States , Antonio Civitarese , Karen Preble , Frederik Nevens , Alexandre Louvet , Lynda Szczech , Nareg Sagherian , M Michelle Berrey , Cheng Zou , Vaclav Hejda , Research Development , Globenewswire Inc , Company On Twitter , Intercept Pharmaceuticals Inc , European Association For The Study , Global Corporate Communications , International Normalized Ratio , Michelle Berrey , Chief Medical Officer , Planned Interim Analysis , Active Controlled Trial Evaluating , Obeticholic Acid , Serum Biomarkers , Primary Biliary , Bezafibrate Fixed Dose , Important Safety Information ,

Verastem Oncology Outlines Key 2023 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib as a Backbone of Therapy for RAS Pathway-Driven Cancers

Verastem Oncology Outlines Key 2023 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib as a Backbone of Therapy for RAS Pathway-Driven Cancers
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Nate Liabraaten , Dan Calkins , Elisa Buffington , Brian Stuglik , Chugai Pharmaceutical Co Ltd , Drug Administration , Balance Sheet To Deliver On Development Milestones , Exchange Commission , Secura Bio Inc , Corporate Communications , Raf And Mek Program , Oxford Finance , Defactinib Combination Advancing , Recurrent Low Grade Serous Ovarian Cancer , Positive Data , Planned Interim Analysis , Confirmatory Study , Accelerated Approval Based , Data Read Outs Planned , Driven Cancers , High Unmet , Balance Sheet , Breakthrough Therapy , Seriesb Convertible Preferred Stock , Verastem Oncology , Preferred Stock ,

Veru Reports Second Quarter Fiscal 2022 Results and Progress of Sabizabulin for COVID-19 Toward a Request for Emergency Use Authorization

12.05.2022 - -FDA States that Veru Should Submit Request for Emergency Use Authorization (EUA) Application Based on Positive Efficacy and Safety Data from the Phase 3 Clinical Study of Sabizabulin in Hospitalized COVID-19 Patients- -IDMC Unanimously Votes to . ....

United States , Mitchell Steiner , Samuel Fisch , Eli Lilly , Sexual Health Division , Data Monitoring Committee , Ar Prostate Cancer Program , Company To Host Investor Conference Call , Exchange Commission , Company Form , Corporate Communications , Breast Cancer Program , Veru Inc , Abemaciclib Combination Therapy , Metastatic Breast Cancer , Host Investor Conference Call Today , Quarter Financial Summary , Date Financial Summary , Chief Executive Officer , Emergency Use , Pipeline Highlights , High Risk , Acute Respiratory Distress Syndrome , Study Unanimously Halted , Independent Data Monitoring Committee , Planned Interim Analysis ,